Kosei Hasegawa

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

Nicoletta Colombo, Coraline Dubot, Domenica Lorusso et al. · New England Journal of Medicine · 2021 · 923 citations · Full text

Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial

Domenica Lorusso, Yang Xiang, Kosei Hasegawa et al. · The Lancet · 2024 · 296 citations

Advanced Cervical Cancer, Cervical Cancer, Cervical Health +9

First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826

Bradley J. Monk, Nicoletta Colombo, Krishnansu S. Tewari et al. · Journal of Clinical Oncology · 2023 · 191 citations

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

Ana Oaknin, Laurence Gladieff, Jerónimo Martínez-García et al. · The Lancet · 2023 · 175 citations

Oncology, Cervical Cancer, Metronomic Therapy +6

Clinically relevant molecular subtypes and genomic alteration-independent differentiation in gynecologic carcinosarcoma

Osamu Gotoh, Yuko Sugiyama, Yutaka Takazawa et al. · Nature Communications · 2019 · 146 citations · Full text

Somatic Variant, Tumor Heterogeneity, Medicine +14